ATE324894T1 - Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen - Google Patents

Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen

Info

Publication number
ATE324894T1
ATE324894T1 AT00904529T AT00904529T ATE324894T1 AT E324894 T1 ATE324894 T1 AT E324894T1 AT 00904529 T AT00904529 T AT 00904529T AT 00904529 T AT00904529 T AT 00904529T AT E324894 T1 ATE324894 T1 AT E324894T1
Authority
AT
Austria
Prior art keywords
beta
d4fc
hiv
didesoxy
fluorocytidine
Prior art date
Application number
AT00904529T
Other languages
English (en)
Inventor
Raymond F Schinazi
Jennifer Hammond
John W Mellors
Dennis C Liotta
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE324894T1 publication Critical patent/ATE324894T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00904529T 1999-01-22 2000-01-21 Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen ATE324894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22

Publications (1)

Publication Number Publication Date
ATE324894T1 true ATE324894T1 (de) 2006-06-15

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904529T ATE324894T1 (de) 1999-01-22 2000-01-21 Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen

Country Status (21)

Country Link
EP (1) EP1143976B9 (de)
JP (1) JP2002535278A (de)
KR (1) KR100745408B1 (de)
CN (2) CN1337880A (de)
AT (1) ATE324894T1 (de)
AU (1) AU781281B2 (de)
BR (1) BR0007627A (de)
CA (1) CA2360039C (de)
DE (1) DE60027691T2 (de)
DK (1) DK1143976T3 (de)
ES (1) ES2263449T3 (de)
HK (1) HK1040064B (de)
IL (1) IL144382A (de)
MX (1) MXPA01007359A (de)
NO (1) NO323586B1 (de)
NZ (1) NZ528156A (de)
PL (1) PL198237B1 (de)
PT (1) PT1143976E (de)
RU (1) RU2254133C2 (de)
WO (1) WO2000043014A2 (de)
ZA (1) ZA200105971B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
US20050244490A1 (en) * 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
WO2005097618A2 (en) 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
WO2006044968A2 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol

Also Published As

Publication number Publication date
KR20020068260A (ko) 2002-08-27
NO323586B1 (no) 2007-06-11
MXPA01007359A (es) 2003-09-22
DE60027691T2 (de) 2007-04-12
PL198237B1 (pl) 2008-06-30
ZA200105971B (en) 2002-10-21
WO2000043014A2 (en) 2000-07-27
IL144382A0 (en) 2002-05-23
AU781281B2 (en) 2005-05-12
HK1040064A1 (en) 2002-05-24
WO2000043014A3 (en) 2000-11-30
EP1143976A2 (de) 2001-10-17
WO2000043014A8 (en) 2001-01-18
IL144382A (en) 2007-02-11
CN101219148A (zh) 2008-07-16
JP2002535278A (ja) 2002-10-22
CA2360039C (en) 2009-11-24
AU2627000A (en) 2000-08-07
DE60027691D1 (de) 2006-06-08
BR0007627A (pt) 2002-04-09
HK1040064B (zh) 2006-07-21
EP1143976B9 (de) 2007-02-14
NO20013599D0 (no) 2001-07-20
CA2360039A1 (en) 2000-07-27
EP1143976B1 (de) 2006-05-03
PT1143976E (pt) 2006-09-29
ES2263449T3 (es) 2006-12-16
KR100745408B1 (ko) 2007-08-02
NO20013599L (no) 2001-09-20
NZ528156A (en) 2005-03-24
CN1337880A (zh) 2002-02-27
RU2254133C2 (ru) 2005-06-20
DK1143976T3 (da) 2006-09-04

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
DE69939705D1 (de) Behandlung der pompeschen krankheit
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
BG104984A (en) 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
TR200002760T2 (tr) HIV engelleyici pirimidin türevleri
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
YU27203A (sh) Pirazol derivati za tretiranje virusnih oboljenja
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE60027691D1 (de) Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5-fluorocytidin für die verwendung in der behandlung von hiv infektionen
DE69328667D1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
EP1731155A3 (de) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine für die verwendung in der behandlung von hiv infektionen
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
DE60025826D1 (de) Pyrazolidinol-verbindungen
KR890001555A (ko) 요산 배설용 조성물
HUP0105469A2 (hu) Pirroloazepineket tartalmazó gyógyászati készítmények claudicatio intermittens kezelésére
RU2000104538A (ru) Способ эндопротезирования тазобедренного сустава при последствиях метатуберкулезного коксита
James PMPA--first human results
TH45970A (th) การบำบัดรักษา hiv ด้วยการใช้ยาร่วมกันของพีกีเลท อินเตอร์ฟิรอนอัลฟา-ตัวต่อต้าน ccr5

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1143976

Country of ref document: EP

REN Ceased due to non-payment of the annual fee